Implications of the FDA approval of PCSK9 Inhibitors and FOURIER Results for Contemporary Cardiovascular Practice: An NCDR(®) Research to Practice (R2P) Project

Podobne knjige/članki

• Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project
  od: Maddox, Thomas M., et al.
  Izdano: (2017)
• Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
  od: Raedler, Lisa A.
  Izdano: (2016)
• Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project
  od: Chau, Katherine Hsin-Yu, et al.
  Izdano: (2019)
• Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia
  od: Fala, Loretta
  Izdano: (2016)
• Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An National Cardiovascular Data Registry (NCDR (®)) Research to Practice (R2P) Project
  od: Mathew, Jehu S., et al.
  Izdano: (2017)